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Introduction
In vitro fertilisation (IVF) and embryo transfer involve
the development of multiple follicles, egg collection,
and the transfer of one or more embryos after fertil-
isation has occurred. Ovarian stimulation is used in
the majority of assisted reproduction units to improve
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Objective. To compare two dosages of recombinant human follicle-stimulating hormone for controlled ovarian
stimulation.
Design. Prospective, randomised double-blind study.
Setting. Tertiary assisted reproduction unit, Hong Kong.
Participants. Forty subfertile Chinese women aged 24 to 38 years undergoing in vitro fertilisation. Entry
criteria included good physical and mental health, and a body mass index between 18 and 29 kg/m2. Exclusion
criteria were subfertility caused by an endocrine abnormality, polycystic ovarian syndrome, or absent ovarian
function; previous assisted reproduction treatment in which fewer than three oocytes were retrieved; prior hos-
pitalisation due to severe ovarian hyperstimulation syndrome; chronic cardiovascular, hepatic, renal, or pulmon-
ary disease; alcohol or drug abuse; and the administration of investigational drugs within the previous 3 months.
Intervention. Injection of recombinant follicle-stimulating hormone, 100 IU/d or 200 IU/d.
Main outcome measures. The number of oocytes, total dose of drug used, and pregnancy rates.
Results. Compared with the 20 women receiving 200 IU/d, the 20 who received 100 IU/d had a significantly
lower median number of oocytes retrieved and median total dose of drug used (7.5 versus 15.0 [P<0.001] and
1200 IU versus 2000 IU [P<0.001], respectively). The pregnancy rates in the fresh cycles were similar (20%) in
both groups, but the cumulative pregnancy rates in the 100 IU/d and 200 IU/d groups were 20.0% and 45.0%
per stimulated cycle, respectively. The incidence of ovarian hyperstimulation syndrome in the 100 IU/d and
200 IU/d groups was 5.0% and 20.0%, respectively.
Conclusions. Use of 100 IU/d of recombinant follicle-stimulating hormone requires a lower total dose but
results in the harvest of half the number of oocytes compared with when a dosage of 200 IU/d is used.
HKMJ 2000;6:368-74
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success rates by increasing the number of oocytes and
thus the number of embryos to be replaced. Gonado-
trophin preparations that are available include urinary
human menopausal gonadotrophin (HMG), which
comprises follicle-stimulating hormone (FSH) 75 IU
and luteinizing hormone (LH) 75 IU; urinary human
FSH (75 IU); and recombinant human FSH.
There is still no consensus on the best starting
doses of gonadotrophins. Most assisted reproduction
units start with FSH in dosages of either 150 IU/d or
225 IU/d for the first 4 days of treatment, after which
the dose is individualised according to the ovarian
response. Recombinant human FSH has been shown
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to be more effective than urinary FSH in IVF/embryo
transfer treatment.1-3 Compared with urinary FSH, a
significantly lower total dose of recombinant FSH
is required and for a shorter period. Furthermore, a
significantly higher number of large follicles, oocytes,
and embryos are obtained with recombinant human
FSH, which results in significantly more ongoing
pregnancies.1-3
Devroey et al4 first reported the use of a 100 IU
starting dose of recombinant human FSH (Puregon;
NV Organon, Oss, The Netherlands) in a group of
43 unselected patients. A multicentre European trial5
that compared 100 IU and 200 IU daily fixed-dose
regimens of Puregon showed similar pregnancy rates
per cycle started, despite more cycles being cancelled
because of low responsiveness and a reduced number
of oocytes in the 100 IU group. These findings suggest
that serum FSH levels are sufficient to stimulate
follicular growth, even in women receiving a lower
starting dose of 100 IU FSH. Data are not available,
however, for Asian or Chinese women, who tend to
be slimmer than European women.
This prospective, randomised double-blind study
aimed to compare the number of oocytes obtained, the
total dose of FSH used, the pregnancy rate, and the
cumulative pregnancy rate between two groups of
subfertile Chinese women using 100 IU/d or 200 IU/d
of recombinant human FSH (Puregon).
Methods
Participants
This study was part of a larger multicentre trial. Women
were recruited from among those attending the Assisted
Reproduction Unit at the Department of Obstetrics
and Gynaecology, The University of Hong Kong,
for IVF treatment from 26 May 1998 to 6 May 1999.
Participants had to satisfy all inclusion and exclusion
criteria. The inclusion criteria used were as follows:
age between 18 and 39 years at the time of screening;
cause of subfertility potentially treatable by IVF or
intracytoplasmic sperm injection (ICSI); normal
ovulatory cycles with a mean duration between 24 and
35 days; good physical and mental health; and a body
mass index of between 18 and 29 kg/m2. The exclu-
sion criteria used were as follows: subfertility caused
by endocrine abnormalities (eg hyperprolactinaemia),
polycystic ovarian syndrome, or the absence of ovar-
ian function; previous assisted reproduction treatment
in which fewer than three oocytes were retrieved; prior
hospitalisation due to severe ovarian hyperstimulation
syndrome (OHSS); chronic cardiovascular, hepatic,
renal, or pulmonary disease; current alcohol or drug
abuse, or a history thereof; and the administration
of investigational drugs within 3 months prior to
screening.
During the screening procedure, patients underwent
a standard protocol of history-taking; a general and
gynaecological examination; and investigations, which
included haematological, biochemical, and hormonal
tests. All eligible women received extensive counsel-
ling and were required to give written consent before
participating in the study, which was approved by the
Ethics Committee, Faculty of Medicine, The Univer-
sity of Hong Kong. The indications for conventional
IVF treatment included tubal infertility, male-factor
infertility, endometriosis, unexplained infertility, and
mixed factors. Intracytoplasmic sperm injection was
performed for couples in which the man had either
severe semen abnormalities (<100 000 motile sperm-
atozoa recovered after sperm preparation) or ob-
structive azoospermia, in which case surgically retrieved
spermatozoa from the epididymis or testis were used.
Ovarian stimulation
The ‘long’ protocol of ovarian stimulation6 was used.
Participants were pretreated with the gonadotrophin-
releasing hormone (gonadorelin) analogue, buserelin
(Suprecur; Hoechst AG, Frankfurt, Germany) 150 m g—
one spray in one nostril—four times daily, from the
mid-luteal phase of the menstrual cycle preceding the
treatment cycle. Pituitary downregulation was con-
firmed by both transvaginal ultrasonography and the
measurement of the serum 17-b -oestradiol (E2) level
on the second day of the treatment cycle. Concentra-
tions of serum levels of FSH, LH, and progesterone
were also measured before the administration of FSH.
The serum hormone concentrations were measured
using commercially available radioimmunoassay kits
(E2 levels: Diagnostic Products Corporation, Los
Angeles, United States; FSH, LH, and progesterone
levels: Chiron Diagnostics Corporation, Massachusetts,
United States).
Participants were randomised to receive recombin-
ant human FSH (follitropin beta [Puregon]) 100 IU/d
or 200 IU/d. They were allocated a number from a
randomisation list that corresponded with patients’
boxes in which the medication was kept. The random-
isation was done in blocks of four and was computer-
generated using random numbers. The recombinant
FSH was supplied as lyophilised spheres in two am-
poules each containing FSH of either 50 IU or 100 IU
in vivo bioactivity. The 50-IU and 100-IU ampoules
were indistinguishable in appearance. The drug in the
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two ampoules was reconstituted with 1 mL of solvent
(0.45% normal saline) and given by subcutaneous
injection.
The ovarian response was monitored by serial
transvaginal ultrasound scanning and by measuring
the serum E2 concentration. Human chorionic gon-
adotrophin (HCG [Pregnyl; NV Organon, Oss, The
Netherlands]) 10 000 IU was given by intramuscular
injection when three leading follicles of >16 mm in
diameter were detected. Transvaginal ultrasound-
guided oocyte collection was scheduled 36 to 38 hours
after the HCG injection. Oocytes were not collected if
women who had been recruited subsequently did not
meet the study criteria and their treatment cycle had
to be cancelled. Blood was taken on the day of HCG
administration to measure serum E2, FSH, LH, and
progesterone concentrations.
Spermatozoa were prepared by using a gradient
separation kit (Isolate; Irvine Scientific, Santa Ana
[CA], United States). Insemination by ICSI was per-
formed 4 to 6 hours after oocyte collection, using
metaphase II oocytes that had been denuded of their
surrounding cumulus and corona radiata cells 2 hours
after their collection by hyaluronidase treatment
(approximately 100 U/mL) and by aspirating oocytes
through a fine capillary. A maximum of three normally
cleaving embryos were replaced into the uterine
cavity 48 hours after oocyte retrieval. Excess good-
quality embryos were frozen for subsequent transfer,
if the woman was not pregnant during the same cycle.
All fresh embryos were cryopreserved if the serum E2
concentration on the day of ovulatory HCG injection
exceeded 30 000 pmol/L, to reduce the risk of OHSS,
which was graded as mild, moderate, or severe.7
The luteal phase was supported by injections of
HCG 1500 IU on the day of embryo transfer and 6 days
later. If, however, the serum E2 concentration on the day
of ovulatory HCG injection exceeded 18 000 pmol/L,
vaginal pessaries of progesterone (Cyclogest; Cox
Pharmaceuticals, Barnstaple, United Kingdom) 400 mg
twice daily were used from the day of the transfer for
10 days. Serum E2 and progesterone levels were meas-
ured 6 days after embryo transfer. A urine pregnancy
test was done 16 days after the transfer. If the result
was positive, an ultrasound examination was performed
10 to 14 days later to confirm intrauterine pregnancy
and to determine the number of gestation sacs present.
Frozen-thawed embryo transfer cycles
Embryos were cryopreserved using a programmable
freezer, with 1,2-propanediol as a cryoprotectant.
Frozen embryos were thawed at room temperature
for 40 seconds and then at 30° C in a water-bath for
40 seconds. The cryoprotectant was then removed
by washing the embryos successively through phos-
phate buffers containing decreasing concentrations
of propanediol. The embryos were cultured in a CO2
incubator for a short period before transfer. Any em-
bryo with half or more of the blastomeres surviving
the freeze-thaw process was transferred. After thaw-
ing, frozen embryos were transferred in natural,
clomifene-induced, or hormonal replacement cycles.6
Statistical analysis
Oocytes were classified as mature or immature, and
embryos were graded as type 1, 2, 3, or 4, according
to published criteria.8 Types 1, 2, and 3 were consid-
ered to be transferable embryos. The fertilisation rate
was defined as the proportion of oocytes that formed
two pronuclei. Only metaphase II oocytes were counted
in ICSI cycles, and only clinical pregnancies were
considered. A clinical pregnancy was defined as the
presence of one or more gestation sacs, and ongoing
pregnancies were those pregnancies beyond 10 to 12
weeks of gestation. The mean implantation rate was
the proportion of embryos transferred that resulted in
the development of an intrauterine gestational sac.
The primary outcome measures were the number
of oocytes obtained and the total dose of FSH used.
Data on the age of the women, type of treatment (IVF
/ICSI), duration of FSH use, number of follicles
aspirated, number of oocytes fertilised, fertilisation
rate, frequency of OHSS development, pregnancy rate,
implantation rate, and the pregnancy outcomes were
compared between the groups. The pregnancy rates in
both fresh and frozen-thawed embryo transfer (FET)
cycles were determined. As the data were not normally
distributed, results were given as median (range).
Statistical tests used were the Mann-Whitney U test,
Fisher’s exact test, and the Chi squared test. A P value
(two-tailed) of <0.05 was considered to be statistically
significant.
Results
A total of 40 women were recruited: 20 in the 100 IU/d
FSH group and 20 in the 200 IU/d FSH group. No
statistically significant differences were found
between the two groups with regard to age, body
mass index, type and duration of infertility, type of
treatment received, and basal FSH level (Table 1).
The number of oocytes obtained in the 100 IU/ group
was significantly less than that in the 200 IU/d
group (7.5 [range, 0-27.0] versus 15.0 [5.0-42.0];
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P<0.001, Mann-Whitney U test). The total dose of
FSH used in the 100 IU/d group was also signifi-
cantly lower than that in the 200 IU/d group (1200 IU
[800-2100] versus 2000 IU [1800-2800]; P<0.001,
Mann-Whitney U test). The secondary indicators of
ovarian response in the two groups are shown in
Table 2. The duration of stimulation in the 100 IU/d
group was 2 days longer than that of the 200 IU/d
group, but this difference was not statistically signifi-
cant. The numbers of follicles with a diameter of
>12 mm, >14 mm, and >16 mm were significantly
higher in the 200 IU/d group. The fertilisation rate
was similar in both groups, but the number of trans-
ferable embryos and number of embryos frozen in
the 100 IU/d group were significantly less than that in
the 200 IU/d group.
There were no differences between the groups in
serum E2, FSH, LH, and progesterone concentrations
on the second day of the treatment cycle (data not
shown). Serum E2, FSH, and progesterone concentra-
tions in the 100 IU/d group were significantly lower
than those in the 200 IU/d group on the day of HCG
administration (Table 2).
Embryo transfer was performed in 16 cycles of the
100 IU/d group and 18 cycles of the 200 IU/d group.
In the 100 IU/d group, three cycles were cancelled
owing to poor ovarian response, and another cycle
was cancelled because of failure of fertilisation. In the
200 IU/d group, no cycle was cancelled because of a
poor ovarian response, but embryo transfer was post-
poned in two cycles because the women had a moder-
ate degree of OHSS. Despite the lower mean number
of embryos replaced in the 100 IU/d group compared
with the 200 IU/d group (1.5 versus 2.0; P=0.035), no
significant differences were observed between the
two groups directly after fresh transfer, in the clinical
pregnancy rate per cycle or per transfer, implantation
rate, and multiple pregnancy rate (Table 3). Two mis-
carriages occurred in the 200 IU/d group, whereas
none occurred in the 100 IU/d group; the ongoing preg-
nancy rates per cycle were 10% and 20%, respectively.
Mild and/or moderate OHSS developed in four women
Table 1. Demographic characteristics of participants receiving 100 IU/d or 200 IU/d Puregon regimens
Characteristic Dosage P value
100 IU/d (n=20) 200 IU/d (n=20)
Age (years)* 34.0 (26-38) 33.0 (24-36) 0.12†
Body mass index (kg/m2)* 21.5 (18.2-25.0) 22.1 (17.8-28.8) 0.17†
Primary/secondary infertility 8/12 12/8 0.21‡
Duration of infertility (years)* 4.0 (2-10) 4.8 (2-14) 0.28†
Type of treatment 0.10†
   in vitro fertilisation 15 10
   intracytoplasmic sperm
   injection 5 10
Basal FSH level (IU/L)* 6.2 (1.0-11.8) 6.7 (1.4-10.5) 0.48†
* Values are expressed as median (range); other characteristics are given as No. of participants
† Mann-Whitney U test
‡ c 2 test
Table 2. Ovarian responses of participants receiving 100 IU/d and 200 IU/d Puregon regimens
Characteristic* Dosage P value†
100 IU/d (n=20) 200 IU/d (n=20)
Duration of stimulation (days) 13 (9-18) 11 (10-15) 0.08
No. of follicles
   >12 mm 7.5 (1.0-14.0) 13.5 (6-25.0) 0.002
   >14 mm 7.5 (1.0-12.0) 11.0 (6.0-18.0) 0.013
   >16 mm 4.5 (1.0-9.0) 6.5 (1.0-17.0) 0.049
17- b -Oestradiol (pmol/L)‡ 8615 (1553-23 600) 13 053 (5760-25 404) 0.028
Follicle-stimulating hormone (IU/L)‡ 6.20 (4.10-8.40) 12.70 (1.20-17.20) <0.001
Luteinizing hormone (IU/L)‡ 1.55 (1.00-3.80) 1.30 (1.00-9.40) 0.36
Progesterone (nmol/L)‡ 2.25 (0.40-9.70) 3.15 (1.00-9.60) 0.009
No. of mature oocytes 7.0 (0-24.0) 13.5 (0-38.0) 0.022
No. of oocytes fertilized 2.5 (0-19.0) 9.0 (4.0-27.0) <0.001
Fertilisation rate (%) 80.0 (0-100) 76.4 (38.9-100) 0.82
No. of transferable embryos 3 (0-16) 8 (3-27) 0.001
No. of embryos replaced 1.5 (0-3.0) 2.0 (0-3.0) 0.035
No. of embryos frozen 0 (0-11) 3 (0-23) 0.014
* All values are expressed as median (range)
† Mann-Whitney U test
‡ Serum concentrations on the day of injection of human chorionic gonadotrophin
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in the 200 IU/d group, whereas only one woman in the
100 IU/d group had mild OHSS (Table 3).
Table 4 shows the outcomes of frozen-thawed
embryo transfers that were performed up to the end of
December 1999 in women who were not pregnant in
the fresh cycle. There was no statistical difference
in the number of FET cycles and the proportion of
embryos that lysed on thawing. The pregnancy rate
in FET cycle, was 27.8% per transfer, and the cumula-
tive pregnancy rates per stimulated cycle in the
100 IU/d and 200 IU/d FSH groups were 20.0% and
45.0%, respectively (P=0.338, Fisher’s exact test).
Discussion
Follicle-stimulating hormone is the key gonadotrophic
hormone during the follicular phase, and only very low
amounts of LH are needed in the different stages of
follicular development and function. Excessive levels
of LH in the early or late follicular phase have adverse
effects on fertilisation, implantation, pregnancy rates,
and early embryonic development.9,10 Gonadotrophin
preparations extracted from postmenopausal urine are
of low purity and may be contaminated up to 95% with
urinary proteins. The impurity may explain the high
incidence of local allergic reactions11 and batch-to-
batch variation12 associated with the use of human
menopausal gonadotrophins. Urinary proteins may
also have negative effects on follicular recruitment and
development.13 Two recent meta-analyses14, 15 have also
suggested that the use of urinary or recombinant FSH
is associated with significantly higher clinical preg-
nancy rates than HMG and that recombinant FSH is
superior to urinary FSH in terms of the pregnancy rate.
The results of this study show a dose-response
relationship between FSH and the number of oocytes
obtained; this finding has also been shown by Out
et al.5 The number of oocytes that were obtained in the
200 IU/d FSH group was twice that obtained in the
100 IU/d group (15.0 versus 7.5). Consequently, the
number of mature oocytes, fertilised oocytes, and trans-
ferable embryos in the 200 IU/d group was higher. The
increase in the number of oocytes in this group was
mainly due to an increase in the number of medium-sized
follicles (ie ranging from 12 to 16 mm in diameter), which
was associated with higher FSH levels on the day of
HCG (Table 2). The progesterone levels on the day of
HCG injection were significantly higher in the 200 IU/d
group and the increased levels are likely to be related
to a greater FSH exposure, thus leading to an increased
FSH-induced LH receptivity in granulosa cells.16
The pregnancy rates per cycle and per transfer were
similar in both groups, despite a slightly higher number
Table 3. Outcomes of fresh cycles in participants receiving 100 IU/d or 200 IU/d Puregon regimens
Outcome measures Dosage P value*
100 IU/d (n=20) 200 IU/d (n=20)
No. of embryo transfers (cycles) 16 18
Clinical pregnancy rate per cycle (%) 20.0 (4/20) 20.0 (4/20) 1.0
Clinical pregnancy rate per transfer (%) 25.0 (4/16) 22.2 (4/18) 1.0
Implantation rate (%) 16.7 (5/30) 11.4 (5/44) 0.735
Multiple pregnancy rate (%) 25.0 (1/4) 25.0 (1/4) 1.0
Pregnancy outcome 0.214
clinical abortion 0 2
ongoing 4 2
No. of cases of ovarian hyperstimulation syndrome
mild 1 2
moderate 0 2
Total 1 4 0.352
* Fisher’s exact test
Table 4. Outcome of frozen-thawed embryo transfer cycles in participants who were not pregnant in the fresh
cycle
Outcome measure 100 IU/d 200 IU/d P value*
No. of cycles with frozen embryos 7 15 0.265
No. of patients attempting FET† 4 11
Total No. of FETs attempted (cycles) 6 18
No. of embryos thawed 13 54
No. of embryos lysed (% of No. thawed) 3 (23) 3 (5) 0.115
No. of pregnancies 0 5
No. of embryos still frozen 9 39
* c 2 test
† FET frozen-thawed embryo transfer
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of embryos being replaced during the fresh cycle in
the 200 IU/d group. When FET cycles were also in-
cluded for consideration, however, the cumulative
pregnancy rate among the women in the 200 IU/d
group was double that of the 100 IU/d group. The
difference was not statistically significant, probably
because of the small sample number. The increase in
the cumulative pregnancy rate was due to there
being more frozen embryos in the 200 IU/d group
than in the 100 IU/d group (median number [range],
3 [0-23] versus 0 [0-11]). Furthermore, more fresh
cycles in the 200 IU/d group had frozen embryos.
The cycle cancellation rates due to poor ovarian
response were 15% (3/20) in the 100 IU/d group and
0% in the 200 IU/d group. A similar rate of cycle
cancellation in the 100 IU/d group was noted by Out
et al.5 Approximately 10% of the cycles in patients
undergoing ovarian stimulation in this study were
cancelled because of poor ovarian response. The
cancellation rate can be highly variable for different
centres, however, because it depends on the character-
istics of patients selected, the type and protocol of
gonadotrophin-releasing hormone agonist used,17 and
the dosage of gonadotrophin given. A higher starting
dose of FSH may reduce the possibility of cycle
cancellation but can lead to a higher risk of the devel-
opment of OHSS. A clear relationship between the total
amount of FSH given and the incidence of OHSS has
been shown by Out et al.5 In this study, the incidence
of OHSS was just 5% in the 100 IU/d group, but it
was 20% in the 200 IU/d group. The difference was
not statistically significant, however, probably because
of the small numbers of patients in this study.
The findings of this study of Chinese women
support the observations in Europe that in a significant
proportion of women, the FSH threshold can be sur-
passed even on a 100 IU fixed daily dose, and result
in multiple follicular development.4,5 The number of
oocytes obtained, the duration and dosage of FSH
used, and the body mass index of the participants in
this study were similar to those reported by Out et al.5
Minimal ovarian stimulation in assisted reproduction
is advocated because of the risks associated with
OHSS.18 We have also shown that the pregnancy rate
may decrease in cycles in which serum E2 levels are
lower than 20 000 pmol/L.6 A logical approach to
determine the dose of gonadotrophin during ovarian
stimulation is to predict the ovarian response and
tailor the dosage accordingly.
Women who are older or obese, or who smoke are
at risk of a poor ovarian response.19 Serum FSH levels
in the early follicular phase and stimulated FSH
levels after a challenge test have been extensively
evaluated to predict the ovarian responses during
ovarian stimulation.19 Ultrasound assessment of the
ovarian volume20,21 and the number of antral follicles22-24
has been recently used to predict the ovarian response.
A higher dose of gonadotrophin could be tried in
women who are more likely to have a poor response
to gonadotrophin stimulation.
In conclusion, a 100 IU fixed daily dose regimen
of recombinant FSH requires a lower total dose of FSH
but results in the harvest of fewer oocytes, compared
with when a 200 IU fixed daily dose is given. The
pregnancy rates in the fresh cycle are similar in both
groups. The chance of cycle cancellation, the risk of
the development of OHSS, and the results of FET
should be taken into consideration when deciding the
starting dose of recombinant FSH. A better prediction
of ovarian response to stimulation is helpful in the
decision-making process.
Acknowledgements
This study was part of a multicentre trial of Puregon
in Asian women, the overall results of which will be
published later. It was supported by a research grant
from NV Organon, Oss, The Netherlands. We would
like to thank Drs EHM Hoomans and BB Mulder
(both from NV Organon) for reviewing the manuscript
and giving constructive comments.
References
1. Devroey P, Mannaerts BM, Smitz J, Coelingh Bennink HJ,
Van Steirteghem A. Clinical outcome of a pilot efficacy study
on recombinant human follicle-stimulating hormone (Org
32489) combined with various gonadotrophin-releasing
hormone agonist regimens. Hum Reprod 1994;9:1064-9.
2. Hedon B, Out HJ, Hugues JN, et al. Efficacy and safety of
recombinant follicle stimulating hormone (Puregon) in infer-
tile women pituitary-suppressed with triptorelin undergoing
in-vitro fertilization: a prospective, randomized, assessor-blind,
multicentre trial. Hum Reprod 1995;10:3102-6.
3. Out HJ, Mannaerts BMJL, Driessen SG, Coelingh Bennink
HJ. A prospective, randomized, assessor-blind, multicentre
study comparing recombinant follicle-stimulating hormone
(Puregon vs Metrodin) in in-vitro fertilization. Hum Reprod
1995;10:2534-40.
4. Devroey P, Tournaye H, Van Steirteghem A, Hendrix P, Out
HJ. The use of a 100 IU starting dose of recombinant follicle
stimulating hormone (Puregon) in in-vitro fertilization. Hum
Reprod 1998;13:565-6.
5. Out HJ, Lindenberg S, Mikkelsen AL, et al. A prospective,
randomized, double-blind clinical trial to study the efficacy
and efficiency of a fixed dose of recombinant follicle
stimulating hormone (Puregon) in women undergoing ovarian
stimulation. Hum. Reprod 1999;14:622-7.
374      HKMJ Vol 6 No 4 December 2000
Ng et al
6. Ng EH, Yeung WS, Lau EY, So WW, Ho PC. High serum
oestradiol levels in fresh IVF cycles do not impair implant-
ation and pregnancy rates in subsequent FET cycles. Hum
Reprod 2000;15:250-5.
7. Royal College of Obstetricians and Gynaecologists. RCOG
Guideline No 5. Management and prevention of ovarian
hyperstimulation syndrome (OHSS). London: RCOG; 1995 Jan.
8. Staessen C, Camus M, Khan I, et al. An 18-month survey of
infertility treatment by in vitro fertilization, gamete and zyg-
ote intrafallopian transfer, and replacement of frozen-thawed
embryos. J In Vitro Fertil Embryo Transfer 1989;6:22-9.
9. Stanger JD, Yovich JL. Reduced in vitro fertilization of
human oocytes from patients with raised basal luteinising
hormone levels during the follicular phase. Br J Obstet
Gynaecol 1985;92:385-93.
10. Homburg R, Armar NA, Eshel A, Adams J, Jacobs HS. Influ-
ence of serum luteinising hormone concentrations on ovula-
tion, conception and early pregnancy loss in polycystic ovary
syndrome. Br Med J 1988;297:1024-6.
11. Phipps WR, Holden D, Sheehan RK. Use of recombinant
human follicle-stimulating hormone for in vitro fertilization-
embryo transfer after severe systemic immunoglobulin E-
mediated reaction to urofollitropin. Fertil Steril 1996;66:
148-50.
12. Rogers M, McLoughlin JD, Lambert A, Robertson WR, Mitchell
R. Variability in the immunoreactive and bioactive follicle
stimulating hormone content of human urinary menopausal
goandotrophin preparation. Hum Reprod 1995;10:1982-6.
13. Giudice F, Crisci C, Eshkol A, Papoian R. Composition of
commercial gonadotropin preparations extracted from human
post-menopausal urine: characterization of non-gonadotropin
proteins. Hum Reprod 1994;9:2291-9.
14. Daya S, Gunby J, Hughes EG, Collins JA, Sagle MA. Follicle-
stimulating hormone versus human menopausal gonadotrophin
for in vitro fertilization cycles: a meta-analysis. Fertil Steril 1995;
64:347-54.
15. Daya S, Gunby J. Recombinant versus urinary follicle
stimulating hormone for ovarian stimulation in assisted
reproduction. Hum Reprod 1999;14:2207-15.
16. Ubaldi F, Camus M, Smitz J, et al. Premature luteinization in
in-vitro fertilization cycles using gonadotropin-releasing hor-
mone agonist (GnRH-a) and recombinant follicle-stimulating
hormone (FSH) and GnRH-a and urinary FSH. Fertil Steril
1996;66:275-80.
17. Hugues JN, Cedrin Durnerin IC Revisiting goadotrophin-
releasing hormone agonist protocols and management of poor
ovarian responses to gonadotrophins. Hum Reprod Update
1998;4:83-101.
18. Fauser BC, Devroey P, Yen SS, et al. Minimal ovarian stimu-
lation for IVF: appraisal of potential benefits and drawbacks.
Hum Reprod 1999;14:2681-6.
19. Sharara FI, Scott RT, Seifer DB. The detection of diminished
ovarian reserve in infertile women. Am J Obstet Gynecol
1998;179:804-12.
20. Lass A, Skull J, McVeigh E, et al. Measurement of ovarian
volume by transvaginal sonography before ovulation induc-
tion with human menopausal gonadotrophin for in-vitro
fertilization can predict poor response. Hum Reprod 1997;12:
294-7.
21. Syrop CH, Dawson JD, Husman KJ, et al. Ovarian volume
may predict assisted reproductive outcome better than follicle
stimulating hormone concentration on day 3. Hum Reprod
1999;14:1752-6.
22. Tomás C, Nuojua-Huttunen S, Martikainen H. Pretreatment
transvaginal ultrasound examination predicts ovarian respon-
siveness to gonadotrophins in in-vitro fertilization. Hum Reprod
1997;12:220-3.
23. Chang MY, Chiang CH, Hsieh TT, et al. Use of the antral
follicle count to predict the outcome of assisted reproductive
technologies. Fertil Steril 1998;69:505-10.
24. Ng EH, Tang OS, Ho PC. The significance of the number of
antral follicles prior to stimulation in predicting ovarian
responses in an in-vitro fertilization programme. Hum Reprod
2000;15:1937-42.
